AXSM Q3 2024 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$105M+81.3% YoY

Gross Profit

$96M91.9% margin

Operating Income

-$63M-59.8% margin

Net Income

-$65M-61.7% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

+20.2%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$18M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$561M

Total Liabilities

$469M

Stockholders' Equity

$93M

Cash & Equivalents

$327M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$105M	$58M	+81.3%
Gross Profit	$96M	$51M	+87.9%
Operating Income	-$63M	-$62M	-0.8%
Net Income	-$65M	-$62M	-3.9%

Revenue Segments

Product

$104M99%

Royalty

$1M1%

Geographic Segments

UNITED STATES

$103M99%

Non-US

$1M1%